Scienture Holdings (SCNX) investor relations material

Strategic focus and business model

• Specializes in branded specialty pharma by improving existing molecules, not discovering new ones.

• Leverages proprietary IP and collaborates with partners for R&D, manufacturing, and commercialization.

• Uses data-driven analysis to identify product opportunities and gaps in the treatment landscape.

• Commercial infrastructure is fully built, enabling efficient product launches and revenue growth.

• Plans to expand internationally after establishing a strong U.S. presence, seeking local partners.

Product portfolio and pipeline

• Two FDA-approved commercial products: an oral liquid losartan for hypertension and REZENOPY™, a 10 mg naloxone nasal spray for opioid overdose.

• Oral liquid losartan addresses a 2%-3% unmet need in a 70 million prescription market.

• REZENOPY™ targets patients needing higher naloxone doses, covering 10%-15% of overdose cases.

• Three pipeline products: a migraine pen injector (SCN-104), a biosimilar for stroke/catheter use (SCN-106), and a long-acting non-opioid postoperative pain injection.

• All products feature significant proprietary IP, with first-in-class delivery mechanisms or formulations.

Commercial operations and market access

• Commercial operations include omnichannel marketing, data-driven targeting, and comprehensive supply chain management.

• Products have national health plan formulary coverage and government reimbursement (Medicare/Medicaid).

• Commercial platform is flexible and scalable, with the ability to tailor field force and marketing to each product.

• Revenue generation began this year, with growth driven by the two launched products.